Nebenwirkungen · Leqembi
LEQEMBI 100 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 9
HOS-150410 · Präparat HOS-100312
The adverse reactions are presented as MedDRA preferred terms under the MedDRA System Organ Class. Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1 000 to <1/100), rare (≥1/10 000 to <1/1 000), very rare (<1/10 000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-05T11:45:00Z · SHA-256 b5b97a1240d6c003d96cd8b3294bef8b3b5d33af33f6be54cfceee548b126f2d · Passage bb93e2065fc44b6aeec739599b187314c50f708edf15f14a2e96e2d5e132062e · Zeichen 1455–1935 im Abschnitt